Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

Rhea-AI Summary

Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on March 28, 2023, at 4:30 pm ET to present a business update and report its financial results for Q4 and full year 2022.

This session can be accessed through dial-in numbers provided or via a live webcast on the company's investor relations website. A replay will be available for 90 days post-call. Corvus is focused on developing innovative therapies, with its lead candidate, CPI-818, currently in a Phase 1/1b trial for T cell lymphomas. Other candidates include CPI-444 and CPI-006, which are in various stages of clinical trials.

Positive

• The company aims to provide a comprehensive business update during the upcoming conference call.
• Corvus Pharmaceuticals is advancing clinical programs like CPI-818, CPI-444, and CPI-006, which target significant medical needs.

Negative

• None.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 28, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2022 financial results.

The conference call can be accessed by dialing 1-844-825-9789 or 1-412-317-5180 (international) or by clicking on this link and requesting a return call and using the conference passcode 3154152. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor that is in an open-label Phase 1b/2 clinical trial. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

When will Corvus Pharmaceuticals hold its conference call for fourth quarter and full year 2022 results?

Corvus Pharmaceuticals will hold its conference call on March 28, 2023, at 4:30 pm ET.

How can I access the Corvus Pharmaceuticals conference call?

You can access the conference call by dialing 1-844-825-9789 or via a live webcast on the Corvus investor relations website.

What is the lead product candidate of Corvus Pharmaceuticals?

The lead product candidate is CPI-818, an investigational drug for T cell lymphomas, currently in Phase 1/1b trials.

What other clinical programs does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals is also developing CPI-444 and CPI-006, focused on A2A receptor inhibition and CD73 targeting, respectively.